Clinical Trials Logo

Melanoma, Uveal clinical trials

View clinical trials related to Melanoma, Uveal.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05655312 Recruiting - Melanoma (Skin) Clinical Trials

MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma

Start date: June 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

In this first-in human, phase I/IIa study, the safety and efficacy of [212Pb]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated in patients with unresectable and metastatic melanoma.

NCT ID: NCT05402059 Recruiting - Melanoma Clinical Trials

Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice

ISABELLA
Start date: March 2, 2022
Phase:
Study type: Observational

Prospective non-interventional study of clinical outcomes and biomarkers in patients with stage 0-IV skin melanoma in real clinical practice

NCT ID: NCT05315258 Recruiting - Melanoma (Skin) Clinical Trials

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

TebeMRD
Start date: July 25, 2022
Phase: Phase 2
Study type: Interventional

Researchers are trying to find ways to improve the management of people with intermediate or high risk resected cutaneous melanoma or with primary uveal melanoma. This research study is investigating using a new blood test to decide when to give a drug called tebentafusp. Tebentafusp has been used in clinical trials in patients with advanced cutaneous and uveal melanoma. This study is designed to determine if tebentafusp can help patients with cutaneous or uveal melanoma live longer.

NCT ID: NCT05308901 Recruiting - Melanoma, Uveal Clinical Trials

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Start date: August 2, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of lenvatinib and pembrolizumab to treat metastatic uveal melanoma.

NCT ID: NCT04729543 Recruiting - Clinical trials for Head and Neck Cancer

MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer

MC2TCR
Start date: October 20, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Single-centre, first-in-man phase I/II trial to demonstrate safety and efficacy of MAGE-C2/HLA-A2 TCR T cells (MC2 TCR T cells) in advanced melanoma (MEL) and head-and-neck carcinoma (HNSCC).

NCT ID: NCT03467516 Recruiting - Melanoma, Uveal Clinical Trials

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

Start date: May 14, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study in which the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with metastatic uveal melanoma will be evaluated. Metastatic uveal melanoma (UM) carries a poor prognosis with estimated survival of 4-6 months. There are no known effective systemic therapies. Metastatic UM is classified as an "orphan" disease and there are currently few clinical trial options for these patients. Thus, novel systemic approaches are desperately needed. A recent pilot study has found that administration of autologous tumor infiltrating lymphocytes (TIL) generated from resected metastases can induce objective tumor response and durable complete response in metastatic uveal melanoma patients. These encouraging results require confirmation to determine if this immunotherapy is of future benefit in treating this disease.